The present disclosure relates to a pharmaceutical composition having a mixture containing curcuminoids as at least one of the active therapeutic agents. Generally, the mixture comprises 4-8% by weight of purified curcuminoids; 20-35% by weight of an oil phase; 25-35% by weight of a co-solvent; and 40-50% by weight of a surfactant. Preferably, the purified curcuminoids in the mixture has an average size of about 19 nm or at least half of the curcuminoids carried in the mixture has particle size not exceeding 19 nm.

Disclosed are compositions, devices, and methods to prevent and recover from detrimental effects of alcohol consumption, including significant undesirable symptoms of a hangover consciously felt by the alcohol consumer, as well as those that may not be consciously experienced. The present technology comprehensively targets multiple negative effects of hangovers. In one aspect, a composition includes dihydromyricetin (DHM); and N-acetyl cysteine (NAC). The composition may further include Prickly Pear Extract, Milk Thistle, Ginger Root, Vitamins B, C, and E, electrolytes, and/or sugars.

The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C.sub.max to serum testosterone C.sub.ave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration C.sub.ave range for a male subject is provided.

Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

The disclosure provides for pharmaceutical compositions comprising an alginate salt, such as sodium alginate. The disclosure further provides for processes and methods for making pharmaceutical compositions. In yet a further aspect, the disclosure provides for methods of utilizing a pharmaceutical composition for treatment of acid reflux diseases. In another aspect, the disclosure provides for formulations suitable for oral use in dosage forms of capsules and dry powders.

An encapsulation method is disclosed for the capture of natural flavors within a clean-label derived from a malt comprising at least partially germinated whole grain seed, pulses, legumes, false grains or flour derived therefrom.

The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

An agent of the present invention comprising poultry feet or a processed product thereof, preferably a hydrolysate of an extract of poultry feet, promotes hyaluronic acid production, thereby exhibiting excellent effects of preventing or treating a joint disorder, improving skin dryness, wrinkles or skin tension, moisturizing the skin, etc. The agent is thus useful as a medicament, a quasi-drug, a cosmetic product, a food product or an animal feed.

Embodiments of the present invention are directed to formulations and methods of treating folic acid deficiency and morning sickness. The dosage form has an effective amount, of a folic add with an effective amount of a gingerol composition to suppress nausea and/or gastric distress and to promote hematopoiesis.

The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.